Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris' Chief Executive Officer and other members of Aclaris' senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

A live and archived webcast will be accessible on the Events page of https://www.aclaristx.com/ . The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ACRS
The Conversation (0)
New Age Metals Expands Bonanza Ridge Gold And Critical Metals Project/Strategic Acquisition Of Lavender Lake & South Gibi Lake Properties

New Age Metals Expands Bonanza Ridge Gold And Critical Metals Project/Strategic Acquisition Of Lavender Lake & South Gibi Lake Properties

(TheNewswire) December 10, 2025 Rockport, Ontario TheNewswire - New Age Metals Inc. (TSX.V: NAM | OTCQB: NMTLF | FSE: P7J) ("NAM" or the "Company") is pleased to announce that effective December 8 th 2025 it has entered into an option agreement, after completing its due diligence, with an... Keep Reading...
New Age Metals Options Magnet Lake Property Further Expanding the Bonanza Ridge Gold & Critical Metals Project, Kenora Mining District, Ontario

New Age Metals Options Magnet Lake Property Further Expanding the Bonanza Ridge Gold & Critical Metals Project, Kenora Mining District, Ontario

(TheNewswire) December 9 th 2025 TheNewswire - Rockport, Ontario New Age Metals Inc. (TSX.V: NAM | OTCQB: NMTLF | FSE: P7J) ("NAM" or the "Company") is pleased to announce that effective December 4, 2025, after completing its due diligence, the Company has entered into an option agreement with... Keep Reading...
Spartan Metals Identifies Two New Tungsten-Silver-Rubidium Targets at its Eagle Project, Nevada

Spartan Metals Identifies Two New Tungsten-Silver-Rubidium Targets at its Eagle Project, Nevada

(TheNewswire) Vancouver, Canada, December 9, 2025 TheNewswire - Spartan Metals Corp. (" Spartan " or the " Company ") (TSX-V: W | OTCQB: SPRMF | FSE: J03) is pleased to announce the discovery of two new tungsten-silver-rubidium exploration targets at the Tungstonia deposit part of the company's... Keep Reading...
Skyharbour and JV Partner Orano Announce Extensive Exploration and Drilling Plans for 2026 at Preston Uranium Project

Skyharbour and JV Partner Orano Announce Extensive Exploration and Drilling Plans for 2026 at Preston Uranium Project

Skyharbour Resources Ltd . (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) ("Skyharbour" or the "Company") is pleased to announce that its joint-venture partner, Orano Canada Inc. ("Orano"), is planning a substantial 2026 exploration and drilling program at the 49,635 hectare Preston Uranium... Keep Reading...
Skyharbour Closes $2.1 Million Private Placement of Flow-Through Shares

Skyharbour Closes $2.1 Million Private Placement of Flow-Through Shares

Skyharbour Resources Ltd . (TSX-V: SYH ) (OTCQX: SYHBF ) (Frankfurt: SC1P ) (the " Company ") is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") financing for total gross proceeds of CAD $2,103,898.94. The Private Placement was mostly subscribed... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News